These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 18829154

  • 1. Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62.
    Staskin DR, Oefelein MG.
    Eur Urol; 2009 Mar; 55(3):e49-50; author reply e51. PubMed ID: 18829154
    [No Abstract] [Full Text] [Related]

  • 2. Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur urol 2008;54:543-62.
    Madersbacher H, Jünemann KP.
    Eur Urol; 2009 Dec; 56(6):e48-9; author reply e50-2. PubMed ID: 19767140
    [No Abstract] [Full Text] [Related]

  • 3. Re: Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26.
    Okpara-Kamanu RI.
    Eur Urol; 2005 Nov; 48(5):873-4. PubMed ID: 16137823
    [No Abstract] [Full Text] [Related]

  • 4. Re: Giacomo Novara, Antonio Galfano, Silvia Secco, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64.
    Staskin DR, Oefelein MG.
    Eur Urol; 2009 May; 55(5):e84-5; author reply e86-7. PubMed ID: 18963417
    [No Abstract] [Full Text] [Related]

  • 5. Editorial comment on: A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
    Cartwright R.
    Eur Urol; 2008 Oct; 54(4):763-4. PubMed ID: 18632200
    [No Abstract] [Full Text] [Related]

  • 6. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms.
    Lemack GE.
    Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351
    [No Abstract] [Full Text] [Related]

  • 7. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P, Berriman SJ, Brodsky M.
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
    Drinka PJ.
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):292-3; author reply 293. PubMed ID: 17062331
    [No Abstract] [Full Text] [Related]

  • 9. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Schaefer W.
    BJU Int; 2009 Feb; 103(4):554-5. PubMed ID: 19187349
    [No Abstract] [Full Text] [Related]

  • 10. Tolterodine for the treatment of overactive bladder.
    Salvatore S, Serati M, Bolis P.
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [Abstract] [Full Text] [Related]

  • 11. Re: Overactive bladder medication adherence when medication is free to patients: C. L. Sears, C. Lewis, K. Noel, T. S. Albright and J. R. Fischer J Urol 2010; 183: 1077-1081.
    Ozkurkcugil C, Ozkan L.
    J Urol; 2010 Oct; 184(4):1575. PubMed ID: 20728905
    [No Abstract] [Full Text] [Related]

  • 12. Local effects of antimuscarinics.
    Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, Yoshimura N.
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [Abstract] [Full Text] [Related]

  • 13. Re: Daniela Marshall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009;55:729-38.
    Ates F, Akyol I, Cirakoglu A.
    Eur Urol; 2009 Jul; 56(1):e1; author reply e2. PubMed ID: 19056165
    [No Abstract] [Full Text] [Related]

  • 14. Overactive bladder: an update.
    Hashim H, Abrams P.
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [Abstract] [Full Text] [Related]

  • 15. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
    Cornel EB.
    Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252
    [No Abstract] [Full Text] [Related]

  • 16. Antimuscarinic treatment for overactive bladder symptoms: an all-time classic, yet still a clinical and basic challenge.
    Apostolidis A.
    Eur Urol; 2011 Mar; 59(3):356-8. PubMed ID: 21195538
    [No Abstract] [Full Text] [Related]

  • 17. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL, Wein AJ.
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [Abstract] [Full Text] [Related]

  • 18. Antimuscarinic drugs to treat overactive bladder.
    Robinson D, Cardozo L.
    BMJ; 2012 Mar 27; 344():e2130. PubMed ID: 22453185
    [No Abstract] [Full Text] [Related]

  • 19. Re: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. A. J. Wein and R. R. Rackley J Urol, suppl., 2006; 175: S5-S10.
    Löfgren OE.
    J Urol; 2007 Oct 27; 178(4 Pt 1):1553; author reply 1553. PubMed ID: 17707052
    [No Abstract] [Full Text] [Related]

  • 20. [Overactive bladder. When it's pressing, immediate help is indicated].
    Widhalm S.
    MMW Fortschr Med; 2008 May 15; 150(20):44-5. PubMed ID: 18605642
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.